Lessons From The Bone Therapeutics/Medsenic Merger With BioSenic's François Rieger, Ph.D.
Business Of Biotech
00:00
The Impact of the Merger on the Biosonic Therapeutic Development
Nellie Zossem: I want to make sure that we spend some time talking about how that affects the forward looking sort of pipeline and candidate development. From Metzenniex it's very clear that we need to succeed because we're the successful phase two trial on the Galvars-Fusos disease chronic form. On the other side with the second lead project is of course coming from Bonta Apetix in terms of the phase two B going on right now. And then we can talk about your existing clinical progress in a little bit.
Transcript
Play full episode
